135 related articles for article (PubMed ID: 15625060)
1. [Assessment of a neuroendocrine tumour by 111In-pentetreotid scintigraphy and PET with 18FFDOPA and 18F-FDG].
Plaza P; Montravers F; Aide N; Carrera D; Kerrou K; Ferran N; Grahek D; Talbot JN
Rev Esp Med Nucl; 2004; 23(6):421-4. PubMed ID: 15625060
[TBL] [Abstract][Full Text] [Related]
2. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
3. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
[TBL] [Abstract][Full Text] [Related]
4. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
[TBL] [Abstract][Full Text] [Related]
5. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
7. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
8. [Metastatic gastroenteropancreatic neuroendocrine tumours: 111In-pentetreotide and PET-FDG imaging].
Serra Arbeloa P; Lancha Hernández C
Rev Esp Med Nucl; 2008; 27(3):199-201. PubMed ID: 18570862
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
11. Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.
Gauthé M; Lièvre A; Alberini JL
Clin Nucl Med; 2015 Nov; 40(11):e516-7. PubMed ID: 26204216
[TBL] [Abstract][Full Text] [Related]
12. Nuclear medicine imaging of neuroendocrine tumours.
Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
[TBL] [Abstract][Full Text] [Related]
13. Novel PET tracers: added value for endocrine disorders.
Bergeret S; Charbit J; Ansquer C; Bera G; Chanson P; Lussey-Lepoutre C
Endocrine; 2019 Apr; 64(1):14-30. PubMed ID: 30875057
[TBL] [Abstract][Full Text] [Related]
14. Best sensitivity of
Testart Dardel N; Montravers F; Triviño-Ibañez E; Gauthé M; Houry S; Talbot JN
Rev Esp Med Nucl Imagen Mol; 2016; 35(6):402-405. PubMed ID: 27246293
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
16. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
17. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
18. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
19. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
20. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
Hoegerle S; Altehoefer C; Ghanem N; Koehler G; Waller CF; Scheruebl H; Moser E; Nitzsche E
Radiology; 2001 Aug; 220(2):373-80. PubMed ID: 11477239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
